GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Livzon Pharmaceutical Group 000513.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

31.32

-0.10%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥11.91bn

FY2016FY2025

Net income

CN¥2.02bn

FY2016FY2025

Free cash flow

CN¥2.60bn

FY2016FY2025

Shareholders' equity

CN¥13.89bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥11.91bnCN¥11.81bnCN¥12.43bnCN¥12.63bnCN¥12.06bnCN¥10.52bnCN¥9.38bnCN¥8.86bnCN¥8.53bnCN¥7.65bn
Gross profitCN¥7.63bnCN¥7.56bnCN¥7.66bnCN¥8.05bnCN¥7.75bnCN¥6.78bnCN¥5.94bnCN¥5.45bnCN¥5.42bnCN¥4.87bn
Research and developmentCN¥842.8mCN¥1.03bnCN¥1.33bnCN¥1.43bnCN¥1.15bnCN¥884.1mCN¥760.4mCN¥616.2mCN¥565.0mCN¥473.2m
Operating incomeCN¥2.62bnCN¥2.84bnCN¥2.42bnCN¥2.35bnCN¥2.27bnCN¥2.50bnCN¥1.73bnCN¥1.27bnCN¥5.66bnCN¥881.3m
Net incomeCN¥2.02bnCN¥2.06bnCN¥1.95bnCN¥1.91bnCN¥1.78bnCN¥1.71bnCN¥1.30bnCN¥1.08bnCN¥4.43bnCN¥784.4m
Diluted earnings per share2.282.242.112.041.891.811.391.174.780.92

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥23.99bnCN¥24.46bnCN¥25.04bnCN¥24.87bnCN¥22.37bnCN¥20.59bnCN¥17.98bnCN¥17.44bnCN¥15.90bnCN¥10.53bn
Cash and short-term investmentsCN¥10.92bnCN¥10.92bnCN¥11.41bnCN¥10.52bnCN¥9.33bnCN¥9.98bnCN¥8.87bnCN¥8.60bnCN¥7.43bnCN¥2.07bn
Total liabilitiesCN¥8.20bnCN¥9.55bnCN¥10.28bnCN¥9.93bnCN¥8.06bnCN¥6.95bnCN¥5.70bnCN¥5.69bnCN¥4.66bnCN¥3.42bn
DebtCN¥3.85bnCN¥3.93bnCN¥3.48bnCN¥3.61bnCN¥2.69bnCN¥1.92bnCN¥1.36bnCN¥1.50bnCN¥663.0mCN¥324.9m
Shareholders' equityCN¥13.89bnCN¥13.86bnCN¥14.04bnCN¥13.88bnCN¥13.00bnCN¥12.11bnCN¥11.17bnCN¥10.65bnCN¥10.77bnCN¥6.51bn
Shares outstanding888m920m924m934m938m947m940m927m926m853m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥3.18bnCN¥2.98bnCN¥3.25bnCN¥2.77bnCN¥1.90bnCN¥2.16bnCN¥1.77bnCN¥1.27bnCN¥1.32bnCN¥1.28bn
Capital spending−CN¥574.1m−CN¥570.2m−CN¥820.5m−CN¥940.1m−CN¥1.31bn−CN¥647.0m−CN¥398.0m−CN¥474.5m−CN¥294.2m−CN¥368.5m
Free cash flowCN¥2.60bnCN¥2.41bnCN¥2.43bnCN¥1.83bnCN¥593.2mCN¥1.51bnCN¥1.37bnCN¥793.1mCN¥1.02bnCN¥910.8m
Dividends paid−CN¥982.1m−CN¥1.34bn−CN¥1.49bn−CN¥1.22bn−CN¥1.17bn−CN¥1.07bn−CN¥868.5m−CN¥1.12bn−CN¥216.3m−CN¥231.1m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥2.13bnCN¥2.87bnCN¥2.90bnCN¥2.84bnCN¥3.09bnCN¥3.18bnCN¥2.73bnCN¥2.80bn
Gross profitCN¥1.17bnCN¥1.89bnCN¥1.83bnCN¥1.91bnCN¥2.06bnCN¥2.07bnCN¥1.59bnCN¥1.86bn
Operating incomeCN¥437.4mCN¥834.3mCN¥365.1mCN¥598.9mCN¥874.6mCN¥958.9mCN¥529.0mCN¥703.1m
Net incomeCN¥355.3mCN¥576.9mCN¥269.1mCN¥473.0mCN¥644.4mCN¥636.7mCN¥388.4mCN¥501.8m
Diluted earnings per share0.400.650.300.530.730.720.420.55
Cash from operations——CN¥625.0mCN¥853.0mCN¥962.0mCN¥724.0mCN¥670.0mCN¥777.0m
Capital spending−CN¥114.0m−CN¥90.0m−CN¥78.0m−CN¥108.0m−CN¥247.0m−CN¥139.0m−CN¥164.0m−CN¥135.0m
Free cash flow——CN¥547.0mCN¥745.0mCN¥715.0mCN¥585.0mCN¥506.0mCN¥642.0m
Total assetsCN¥23.59bnCN¥24.19bnCN¥23.99bnCN¥24.54bnCN¥24.17bnCN¥24.49bnCN¥24.46bnCN¥24.91bn
Cash and short-term investments——CN¥10.92bnCN¥11.04bnCN¥10.61bnCN¥10.90bnCN¥10.92bnCN¥10.81bn
DebtCN¥25.9mCN¥158.0mCN¥3.83bnCN¥3.29bnCN¥3.50bnCN¥3.76bnCN¥3.92bnCN¥2.46bn
Shareholders' equityCN¥13.37bnCN¥14.51bnCN¥13.89bnCN¥13.96bnCN¥13.68bnCN¥14.17bnCN¥13.86bnCN¥14.16bn

Financial ratios

Data as of 23 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin64.1%64.0%61.6%63.8%64.3%64.4%
Operating margin22.0%24.1%19.4%18.6%18.8%23.8%
Net margin17.0%17.4%15.7%15.1%14.7%16.3%
Return on equity14.6%14.9%13.9%13.8%13.7%14.2%
Return on assets8.4%8.4%7.8%7.7%7.9%8.3%
Free cash flow yield15.2%13.9%15.9%14.3%12.3%10.7%
Revenue growth0.8%-5.0%-1.6%4.7%14.7%12.1%
Earnings growth-1.8%5.5%2.3%7.5%3.5%31.6%
Current ratio2.23x2.15x2.14x2.30x2.12x2.40x
Debt to equity0.28x0.28x0.25x0.26x0.21x0.16x
Equity ratio57.9%56.7%56.1%55.8%58.1%58.8%
Interest coverage42.50x30.58x22.59x22.81x25.80x82.34x
R&D as a share of sales7.1%8.7%10.7%11.3%9.5%8.4%
Buybacks as a share of market value3.5%0.4%1.1%0.4%1.0%-0.7%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-1.9%2.5%6.0%
Operating income3.7%1.0%14.2%
Net income1.9%3.4%12.5%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin64.1%63.4%63.7%63.3%
Operating margin23.1%21.0%21.0%22.5%
Net margin17.2%16.3%16.0%17.5%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings15.117.016.615.921.222.424.316.68.229.4
Price to sales2.63.02.62.43.13.63.42.04.33.0

Dividends and splits

Per share, in the currency the company pays

Paid for 18 years. Last went ex-dividend on 16 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year1.431.101.351.601.301.251.150.923
  • 13-for-10 split · 3 Jul 2019
  • 13-for-10 split · 22 Jun 2018
  • 13-for-10 split · 7 Jul 2017
  • 13-for-10 split · 14 Aug 2015
  • 1-to-1 reverse split · 11 Dec 2006

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.